Description
N6-Methyladenosine (m6A) is an abundant modification found in mRNA, tRNA, snRNA, as well as long non-coding RNA, in all species. RNA adenosine methylation is catalyzed by a multicomponent complex composed of METTL3/MT-A70, METTL14, and WTAP in mammals. METTL3 and METTL14 are responsible for the methyltransferase activity of the complex, and WTAP mediates substrate recruitment.{30057} The process shares similarities to histone methylation in that the modification is installed by m6A methylation “writers”, detected by methylation-specific “readers”, and can be reversed by demethylation “erasers”. The m6A modification has been shown to be conserved in the vicinity of stop codons and the 3’-untranslated region of specific mouse and human mRNAs.{25677} The process of regulating m6A modifications in mammalian mRNA has been linked to disease, where fat mass and obesity-associated (FTO) has been reported to be an obesity risk gene.{25677} FTO is an m6A demethylase and polymorphisms that result in increased FTO expression are associated with increased body mass and risk of obesity. Cayman’s N6-Methyladenosine Monoclonal Antibody (Clone 17-3-4-1) can be used for dot blot, ELISA, and immunoprecipitation applications.
Synonyms: m6A
Immunogen: N6-Methyladenosine conjugated to BSA
Formulation: 100 µg of protein A-purified antibody
Isotype: IgG1k
Applications: Dot blot, ELISA, IP
Origin:
Stability: 365 days
Application|ELISA||Application|Enzyme Activity||Application|Immunoprecipitation||Product Type|Antibodies|Monoclonal Antibodies||Research Area|Epigenetics, Transcription, & Translation|Writers|DNA/RNA Methylation
